Literature DB >> 28447312

Bone Quality in Chronic Kidney Disease: Definitions and Diagnostics.

Erin M B McNerny1,2, Thomas L Nickolas3,4.   

Abstract

PURPOSE OF REVIEW: In this paper, we review the epidemiology, diagnosis, and pathogenesis of fractures and renal osteodystrophy. RECENT
FINDINGS: The role of bone quality in the pathogenesis of fracture susceptibility in chronic kidney disease (CKD) is beginning to be elucidated. Bone quality refers to bone material properties, such as cortical and trabecular microarchitecture, mineralization, turnover, microdamage, and collagen content and structure. Recent data has added to our understanding of the effects of CKD on alterations to bone quality, emerging data on the role of abnormal collagen structure on bone strength, the potential of non-invasive methods to inform our knowledge of bone quality, and how we can use these methods to inform strategies that protect against bone loss and fractures. However, more prospective data is required. CKD is associated with abnormal bone quality and strength which results in high fracture incidence.

Entities:  

Keywords:  Bone mineral density; Bone quality; Dialysis; Fracture; Kidney; Renal osteodystrophy

Mesh:

Year:  2017        PMID: 28447312      PMCID: PMC5558885          DOI: 10.1007/s11914-017-0366-z

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  60 in total

1.  Influence of nonenzymatic glycation on biomechanical properties of cortical bone.

Authors:  D Vashishth; G J Gibson; J I Khoury; M B Schaffler; J Kimura; D P Fyhrie
Journal:  Bone       Date:  2001-02       Impact factor: 4.398

2.  In vivo assessment of bone quality in postmenopausal women with type 2 diabetes.

Authors:  Joshua N Farr; Matthew T Drake; Shreyasee Amin; L Joseph Melton; Louise K McCready; Sundeep Khosla
Journal:  J Bone Miner Res       Date:  2014-04       Impact factor: 6.741

3.  Intact PTH combined with the PTH ratio for diagnosis of bone turnover in dialysis patients: a diagnostic test study.

Authors:  Johann Herberth; Adam J Branscum; Hanna Mawad; Tom Cantor; Marie-Claude Monier-Faugere; Hartmut H Malluche
Journal:  Am J Kidney Dis       Date:  2010-03-27       Impact factor: 8.860

Review 4.  Bone's Material Constituents and their Contribution to Bone Strength in Health, Disease, and Treatment.

Authors:  Y Bala; E Seeman
Journal:  Calcif Tissue Int       Date:  2015-02-25       Impact factor: 4.333

5.  Alterations of bone microstructure and strength in end-stage renal failure.

Authors:  A Trombetti; C Stoermann; T Chevalley; B Van Rietbergen; F R Herrmann; P-Y Martin; R Rizzoli
Journal:  Osteoporos Int       Date:  2012-10-26       Impact factor: 4.507

6.  Bone mineral density by DXA and HR pQCT can discriminate fracture status in men and women with stages 3 to 5 chronic kidney disease.

Authors:  S A Jamal; A M Cheung; S L West; C E Lok
Journal:  Osteoporos Int       Date:  2012-12       Impact factor: 4.507

7.  Bone Tissue Properties Measurement by Reference Point Indentation in Glucocorticoid-Induced Osteoporosis.

Authors:  Leonardo Mellibovsky; Daniel Prieto-Alhambra; Fernando Mellibovsky; Roberto Güerri-Fernández; Xavier Nogués; Connor Randall; Paul K Hansma; Adolfo Díez-Perez
Journal:  J Bone Miner Res       Date:  2015-06-11       Impact factor: 6.741

8.  Increased risk of hip fracture among patients with end-stage renal disease.

Authors:  A M Alem; D J Sherrard; D L Gillen; N S Weiss; S A Beresford; S R Heckbert; C Wong; C Stehman-Breen
Journal:  Kidney Int       Date:  2000-07       Impact factor: 10.612

9.  Relationship between moderate to severe kidney disease and hip fracture in the United States.

Authors:  Thomas L Nickolas; Donald J McMahon; Elizabeth Shane
Journal:  J Am Soc Nephrol       Date:  2006-09-27       Impact factor: 10.121

10.  High rates of death and hospitalization follow bone fracture among hemodialysis patients.

Authors:  Francesca Tentori; Keith McCullough; Ryan D Kilpatrick; Brian D Bradbury; Bruce M Robinson; Peter G Kerr; Ronald L Pisoni
Journal:  Kidney Int       Date:  2013-07-31       Impact factor: 10.612

View more
  21 in total

1.  Skeletal levels of bisphosphonate in the setting of chronic kidney disease are independent of remodeling rate and lower with fractionated dosing.

Authors:  Elizabeth A Swallow; Mohammad W Aref; Corinne E Metzger; Spencer Sacks; Demi R Lehmkuhler; Neal Chen; Max A Hammond; Paul R Territo; Thomas L Nickolas; Sharon M Moe; Matthew R Allen
Journal:  Bone       Date:  2019-07-09       Impact factor: 4.398

2.  Skeletal accumulation of fluorescently tagged zoledronate is higher in animals with early stage chronic kidney disease.

Authors:  E A Swallow; M W Aref; N Chen; I Byiringiro; M A Hammond; B P McCarthy; P R Territo; M M Kamocka; S Winfree; K W Dunn; S M Moe; M R Allen
Journal:  Osteoporos Int       Date:  2018-06-11       Impact factor: 4.507

3.  Chronic kidney disease-related osteoporosis is associated with incident frailty among patients with diabetic kidney disease: a propensity score-matched cohort study.

Authors:  C-T Chao; J Wang; J-W Huang; D-C Chan; K-Y Hung; K-L Chien
Journal:  Osteoporos Int       Date:  2020-02-27       Impact factor: 4.507

4.  The HIF-PHI BAY 85-3934 (Molidustat) Improves Anemia and Is Associated With Reduced Levels of Circulating FGF23 in a CKD Mouse Model.

Authors:  Megan L Noonan; Pu Ni; Rafiou Agoro; Spencer A Sacks; Elizabeth A Swallow; Jonathan A Wheeler; Erica L Clinkenbeard; Maegan L Capitano; Matthew Prideaux; Gerald J Atkins; William R Thompson; Matthew R Allen; Hal E Broxmeyer; Kenneth E White
Journal:  J Bone Miner Res       Date:  2021-03-10       Impact factor: 6.741

Review 5.  Updates in CKD-Associated Osteoporosis.

Authors:  Pascale Khairallah; Thomas L Nickolas
Journal:  Curr Osteoporos Rep       Date:  2018-12       Impact factor: 5.096

6.  Comparison of clinical, biochemical and histomorphometric analysis of bone biopsies in dialysis patients with and without fractures.

Authors:  Melissa F P Santos; Mariel J Hernández; Ivone B de Oliveira; Flávia R Siqueira; Wagner V Dominguez; Luciene M Dos Reis; Aluizio B Carvalho; Rosa M A Moysés; Vanda Jorgetti
Journal:  J Bone Miner Metab       Date:  2018-01-25       Impact factor: 2.626

Review 7.  Rethinking Bone Disease in Kidney Disease.

Authors:  Matthew J Damasiewicz; Thomas L Nickolas
Journal:  JBMR Plus       Date:  2018-11-15

8.  Bone matrix mineralization and osteocyte lacunae characteristics in patients with chronic kidney disease - mineral bone disorder (CKD-MBD).

Authors:  Barbara M Misof; Stéphane Blouin; Paul Roschger; Johannes Werzowa; Klaus Klaushofer; Gabriele Lehmann
Journal:  J Musculoskelet Neuronal Interact       Date:  2019-06-01       Impact factor: 2.041

Review 9.  Assessing bone mineralisation in children with chronic kidney disease: what clinical and research tools are available?

Authors:  A D Lalayiannis; N J Crabtree; M Fewtrell; L Biassoni; D V Milford; C J Ferro; R Shroff
Journal:  Pediatr Nephrol       Date:  2019-06-25       Impact factor: 3.714

Review 10.  A Review on Bone Mineral Density Loss in Total Knee Replacements Leading to Increased Fracture Risk.

Authors:  M Gundry; S Hopkins; K Knapp
Journal:  Clin Rev Bone Miner Metab       Date:  2017-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.